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Abstract
Background: Cancer is a major cause of mortality and morbidity in patients with chronic kidney disease (CKD). In
patients without kidney disease, screening is a major strategy for reducing the risk of cancer and improving the
health outcomes for those who developed cancers by detecting treatable cancers at an early stage. Among those
with CKD, the effectiveness, the efficacy and patients’ preferences for cancer screening are unknown.
Methods/Design: This work describes the protocol for the DETECT study examining the effectiveness, efficiency
and patient’s perspectives of colorectal cancer screening using immunochemical faecal occult blood testing (iFOBT)
for people with CKD. The aims of the DETECT study are 1) to determine the test performance characteristics of
iFOBT screening in individuals with CKD, 2) to estimate the incremental costs and health benefits of iFOBT
screening in CKD compared to no screening and 3) to elicit patients’ perspective for colorectal cancer screening in
the CKD population. Three different study designs will be used to explore the uncertainties surrounding colorectal
cancer screening in CKD. A diagnostic test accuracy study of iFOBT screening will be conducted across all stages of
CKD in patients ages 35-70. Using individually collected direct healthcare costs and outcomes from the diagnostic
test accuracy study, cost-utility and cost-effective analyses will be performed to estimate the costs and health
benefits of iFOBT screening in CKD. Qualitative in-depth interviews will be undertaken in a subset of participants
from the diagnostic test accuracy study to investigate the perspectives, experiences, attitudes and beliefs about
colorectal cancer screening among individuals with CKD.
Discussion: The DETECT study will target the three major unknowns about early cancer detection in CKD. Findings
from our study will provide accurate and definitive estimates of screening efficacy and efficiency for colorectal
cancer, and will allow better service planning and budgeting for early cancer detection in this at-risk population.
The DETECT study is also registered with the Australia New Zealand Clinical Trials Registry ACTRN12611000538943
Background
After cardiovascular disease, the second most common
cause of death in people with CKD is cancer(1,2). CKD
both increases the risk of cancer and the likelihood of a
poor prognosis. A two to three-fold increase in the over-
all cancer incidence had been reported in the dialysis
and transplant populations(3), and in people with mod-
erate CKD (stages III and IV). The development of
cancer in people with CKD is associated with an excess
risk of death of about 20-30% compared with those with
cancer with normal kidney function. The increased risk
of cancer in the transplant population is largely attribu-
ted to the effects of immunosuppression use. Among
those with moderate CKD and on dialysis, the biological
rationale for the increased risk remains unclear. Some
have proposed the increased risk of cancer development
may be due to the effects of chronic inflammation and
uraemia, but there is a lack of definitive epidemiological
and biological evidence to show a direct casual relation-
ship(4,5).
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Colorectal cancer and CKD
Colorectal cancer is the second most common cause of
solid organ cancer in recipients of kidney transplants
and those on dialysis, with an excess risk of at least 2.5
and 1.4 times that of the age and gender matched gen-
eral population(3). For colorectal cancer, the increase in
risk is greatest for younger patients (ages 35-40) with a
standard incidence ratio (SIR) of 13.5, and a SIR of 2.3
among older individuals (ages > 55) compared to the
age and gender matched general population(6). Survival
of these patients is also poor. One-year survival after
colorectal cancer diagnosis is less than 50% for patients
with a kidney transplant, and less than 30% for dialysis
patients, with only 10% of dialysis patients survival 5
years after initial diagnoses(2).
Screening for colorectal cancer in the general population
There is strong evidence that screening for colorectal
cancer using FOBT is effective and reduces cancer-spe-
cific mortality by at least 16-33%(7). Population screen-
ing for colorectal cancer is recommended and applied in
the general population worldwide. In England, the
National Health Service (NHS) bowel cancer screening
program was developed in 2006 and phased in over a
period of 3 years for people aged 60-69. Similar pro-
grams were also developed in Scotland, Wales and
Northern Ireland, with a recent extension of the Welch
and English program extending to men and women
aged 70 - 74(8-10). In Australia, iFOBT was first offered
to those aged 50, 55 and 65 as part of the initial roll-out
of the National Bowel Cancer Screening Program in
2006(11-14). Recent initiatives by cancer advocates and
research groups have led to the continuing funding of
the Program by the Australian Government in the next
five years(15). Although other countries such as Canada,
Netherlands, Denmark and Spain do not have a national
bowel cancer screening program, various pilots pro-
grams and studies are now underway to assess the effec-
tiveness of bowel cancer screening (16).
IFOBT is an accurate test, with studies among the gen-
eral population reporting a test specificity and sensitivity
of at least 80% and 75% respectively(7,17-20). Population
screening using iFOBT is also well-accepted by the gen-
eral population. iFOBT is a simple and user-friendly test,
which performs well, compared to other screening strate-
gies such as flexible sigmoidoscopy in the general popula-
tion. IFOBT screening for colorectal cancer is also cost-
effective, with an estimated incremental cost-effective-
ness ratio of less than $50,000 per QALY compared to
no screening in the general population(13,14,21).
Screening for colorectal cancer in the CKD population
Unlike screening in people without kidney disease, the
costs, benefits, harms of cancer screening in the CKD
population is largely unknown. We have conducted a
series of systematic reviews and modelled economic eva-
luations of cancer screening in people with CKD, and
found key sources of uncertainty around: patients’ pre-
ferences and the costs and health outcomes of early can-
cer detection, the screening test accuracy in CKD, the
treatment outcomes and the quality of life of patients
with cancer and CKD(13,14,21,22). As such, we have
four main reasons for conducting this program of work:
1. The extent of benefits and harms of screening and
the screening test characteristics from the general popu-
lation are not generalisable to individuals with CKD
The performance of the screening test may change
when it is applied to different patient subgroups due to
the issues of spectrum bias. Higher rates of minute gas-
trointestinal mucosal bleeding are expected in indivi-
duals with CKD because of anti-coagulation use during
dialysis, potential uraemic induced platelet defects and
the use immunosuppressive agents leading to possible
adverse effects on test specificity. Furthermore, previous
studies have also shown that the test sensitivity rate
increases with the use of low-dose aspirin by increasing
the likelihood of bleeding from colorectal neoplasms in
the general population(23,24). It is unclear whether low-
dose aspirin, or other anti-platelet agents, which are
used frequently in the CKD population for the primary
and secondary prevention of cardiovascular disease, will
have the similar effects on the iFOBT test performance
characteristics.
Screening may also be less effective because of higher
competing risks of death and lower life expectancy.
Many have advocated against routine screening for can-
cer in patients with end-stage kidney disease (ESKD)
because of competing risks of deaths from causes other
than cancers(25,26). Some studies have questioned the
benefits of screening in people with co-existing co-mor-
bidities and chronic illness such as those with CKD.
Previous modelled analyses have shown that people with
several chronic conditions such as kidney and lung dis-
eases have a substantially lower gain in life expectancy
associated with early stage cancer at diagnosis compared
to those without chronic diseases(25,26). However, there
is limited information about the types of chronic ill-
nesses and how the aggregation of chronic conditions
identifies those who will benefit the most from early
cancer detection.
There may also be differences in the potential risk of
harms associated with screening in patients with CKD.
Identifying trivial and insignificant diseases may lead to
unnecessary anxiety; patients may also be treated for
disease, which may never be destined to become clini-
cally significant (diagnoses of inconsequential diseases).
The screening process may even be more harmful for
those with chronic illness such as CKD. For example,
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subjecting people with reduced kidney function and
coexisting cardiac disease to colonoscopic investigations
after positive iFOBTs may be detrimental because of the
higher risk of cardiovascular events associated with
anaesthesia. In addition, previous studies have also
reported a higher than expected incidence of bacterial
peritonitis among individuals on peritoneal dialysis who
have undergone colonoscopic polypectomies(27,28).
2. There are evidence gaps between guidelines and
screening practices for screening colorectal cancer in
CKD.
Our previous work, through systematic reviews and
extensive modelled analyses, reports substantial uncer-
tainties regarding the benefits and harms of screening in
the context of CKD(22,29,30). Guidelines for screening
in patients with reduced kidney function are generally
extrapolated from the general population without vali-
dated data to support or refute the standard recom-
mended practice. There are also considerable
inconsistencies in the recommendations for colorectal
cancer screening in CKD patients between countries
and regions. The American Transplantation Society
recommends annual FOBT screening and flexible sig-
moidoscopy screening for all transplant recipients ages
50 years and above(31), whereas the European Best
Practice guidelines suggested the use of annual FOBT
screening in all transplant recipients above 50 years, in
accordance to the national recommendations for the
general population(32).
3. There are uncertainties about the cost-effectiveness
of screening in CKD
Economic modelling provides an understanding of the
potential costs and benefits of colorectal cancer screen-
ing and is useful to help inform decisions about imple-
mentation of population screening programs. Economic
models in the general population have shown that full
implementation of the biennial bowel cancer screening
program in Australia using iFOBT would reduce bowel
cancer mortality and would be an efficient use of limited
health resources(13,14). Unlike screening in the general
population, analyses of screening colorectal cancer in
the transplant population has indicated substantial
uncertainties regarding the estimates of the diagnostic
test accuracy of iFOBT the transplant population(22).
Using the individually-collected costs and clinical esti-
mates from the diagnostic test accuracy study, our trial
and modelled economic evaluations will inform clini-
cians and policy-makers of the direct healthcare costs
and effectiveness (health outcomes) of screening com-
pared with no screening in the CKD population.
4. The perspectives and preferences on colorectal can-
cer screening of the CKD population are unclear
Understanding individuals’ perspectives and prefer-
ences is necessary to inform and support the
development of policies to improve patient engagement
and empowerment in decision-making about their own
health. Despite the established increased risk of cancer
in people with kidney disease, patients with CKD are
often understandably preoccupied with the burden of
co-existing illnesses such as cardiovascular disease and
the complicated dialysis regimens, and may consider the
non-imminent issues such as cancer prevention and
screening as trivial. Recognising the needs, perspectives
and priorities of individual’s views and perspectives is
paramount to optimise shared decision-making between
patients and healthcare providers, and to improve the
responsiveness and effectiveness of preventive health
care delivery in this at-risk population.
The aims of the DETECT study are to:
1. Determine the test performance characteristics
iFOBT screening among individuals with CKD
2. Estimate the incremental costs and health out-
comes, and the cost-effectiveness of iFOBT screening
compared to no screening in the CKD population
3. Elicit the perspectives and preferences of iFOBT
screening among individuals with CKD
Methods/Designs
Overview of approach and methods
The DETECT study will utilise both qualitative and
quantitative methods to investigate screening colorectal
cancer in individuals with CKD. A diagnostic test accu-
racy study, a cost-effectiveness/cost-utility analysis and
qualitative in-depth interviews will be conducted to
examine the efficacy, the efficiency and patient perspec-
tives and preferences of colorectal cancer screening in
CKD.
Study design 1: Diagnostic test accuracy study
A diagnostic test accuracy study will be conducted in
the CKD population. The design, the conduct and the
reporting of this study is in accordance with the STARD
initiatives(33).
Patient recruitment and eligibility Patients ages 35-70,
with CKD (stages III-V), CKD-dialysis and CKD-trans-
plant will be recruited from the three main area health
services in N.S.W. Although the recommended age for
colorectal cancer screening in the general population
commences at 50(11), but given the relative increased
risk of cancer in the younger transplant population(6)
and the greater risk of dying from cardiovascular related
causes in the older CKD individuals(34), expansion of
the study to include the younger pre-dialysis, dialysis
and transplant population is clinically appropriate, and
will capture the population that may benefit the most
from early cancer detection. Informed consent (verbal
and written) will be obtained from all participants.
Exclusion criteria Patients who have a first-degree rela-
tive with colorectal cancer or a personal history of
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colorectal cancer and inflammatory bowel disease, a
recent FOBT test (less than one year), who have had a
colonoscopy performed within two years, who are medi-
cally unfit for a colonoscopy, who are pregnant and who
have active gastrointestinal bleeding will be excluded
from the study.
Baseline data collection The following information will
be collected at baseline. They include: age, gender, self-
reported race, co-morbidities, medication use, self and
any family history of cancer.
Quality of life (QoL) data will also be collected from
all enrolled participants at baselines, after the initial
IFOBT screen and after the diagnostic colonoscopy at
day 14. We will be using two generic QoL assessment
tools: the SF-36 and the Euro-Qol (EQ5D) to capture
the QoL associated with screening and the diagnostic
procedures.
Screening procedure Eligible participants will be invited
to perform the screening tests using the iFOBT kit(35).
Two consecutive faecal samples will be required for a
single test kit. Test positivity is defined as 100 ng/ml of
haemoglobin in either one of the two stool samples
Diagnostic procedures All participants with positive
iFOBT screens will be invited to undergo subsequent
diagnostic colonoscopies. If polyps are found, polypec-
tomies will be conducted at the time of the diagnostic
procedure. If advanced mucosal neoplasia is found, it
will be planned for endoscopic mucosal resection (EMR)
at a separate procedure. Advanced neoplasia is defined
as adenoma with at least one of the following features: 1
cm or more in size, tubulovillous or villous components,
or high-grade dysplasia, or any advanced neoplasm 1 cm
or more in diameter. EMR is used increasingly fre-
quently for minimally invasive curative resection of
benign and early-stage malignant lesions (T1a) through-
out the gastrointestinal tract. EMR has the advantage of
managing large, sessile polyps in the outpatient setting,
which is potentially cost-saving and may improve clini-
cal outcomes in this high risk cohort(36).
All cancers identified will be staged and the partici-
pants will be referred to the colorectal surgical and
oncology team, depending upon the stage of initial diag-
noses. All cancer diagnoses will be reported to the Cen-
tral Cancer Registry of New South Wales (located
within the Cancer Institute of NSW) for all patients
with CKD, and the Australia and New Zealand Dialysis
and Transplant Registry (ANZDATA) for those on renal
replacement therapy (CKD-dialysis and CKD-trans-
plant). The ANZDATA registry is comprehensive data-
base that prospectively collects information on all
patients on renal replacement therapy in Australia and
New Zealand since 1963. The clinical data includes
records of all new cancers except for squamous and
basal cell carcinomas. Notification of malignant cancers
is a statutory requirement for all health-related institu-
tions in New South Wales. The Central Cancer Registry
of New South Wales contains all cancer records and the
identifying information for patients diagnosed and trea-
ted with cancer within the state of New South Wales
since 1972.
Reference standard Clinical follow-up will be the refer-
ence standard for all participants. All participants, with
or without screen positive results, will be followed clini-
cally two years after their initial screen. To ensure ade-
quate follow-up and accurate calculation of the
screening test performance characteristics of cancer, we
will compare our records with that of the Central Can-
cer Registry (CCR) of NSW through data linkage at 2, 5
and 7 years after the initial screens with the attempt to
capture all cancer diagnoses.
Outcomes The outcomes of the study will include the
following:
1. Prevalence of colorectal cancer and advanced color-
ectal neoplasia in patients with CKD
2. Screen positivity rate: defined as the proportion of
participants with positive screens in the total screened
study population
3. Test sensitivity: defined as the number of colorectal
cancers and/or advanced neoplasms detected through
screening divided by the total number of colorectal can-
cers and/or advanced neoplasms detected through
screening and the total number of cancers and/or
advanced neoplasms occurring within the delay in a
given period (the follow-up time) after a negative screen.
4. Test specificity: defined as the number of partici-
pants with no colorectal cancers and/or advanced neo-
plasms within the follow-up period divided by the
number of participants with no colorectal cancers and/
or advanced neoplasms after a negative screen and the
number of participants without colorectal cancers and/
or advanced neoplasms after a positive screen within the
follow-up period.
5. Participation rate of screening among individuals
with CKD.
6. Potential harms of screening and the diagnostic
colonoscopies, such as bleeding, bowel perforation and
the inherent risks of peritonitis, particularly among peri-
toneal dialysis patients.
7. Direct healthcare costs, including individually- col-
lected screening, diagnostic, treatment and overhead
costs.
Statistical analyses and sample size calculations
Sensitvity and specificity of iFOBT screening for
advanced colorectal neoplasia and cancer will be esti-
mated for (i) CKD (stages 3-5) patients, (ii) dialysis
patients, and (iii) transplant patients. For each estimate,
the required sample size will be determined by the
combined expected prevalence of advanced neoplasia
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and cancer, the expected sensitivity and specificity, and
the required precision of the estimated maximum 90%
confidence interval width. For each of the three patient
groups, the sensitivity is expected to be 75% and the
maximum required 90% confidence interval width is ±
10%. Therefore, 51 cases of advanced neoplasms and
cancer will be required. The total sample size and the
precision of the estimates of specificity (which is
expected to be 90%) for each patient group will be
determined by the expected prevalence for that group.
In the CKD stages (3-5) group (with a one-year com-
bined estimated prevalence of disease equals to 3.1%), a
total of 1637 patients would yield 51 cases and 1586
non-cases. The maximum 90% confidence interval
width for specificity is ± 1.3%. Among those on dialysis
(with a one-year combined prevalence of disease equals
to 3.94%), a total of 1288 patients would yield 51 cases
and 1237 non-cases, giving a maximum 90% confidence
interval width for specificity of ± 1.4%. Assuming a
one-year combined prevalence of disease equals to
4.2% in the transplant population, a total of 1208
patients will again yield a total of 51 cases and 1157
non-cases, giving a maximum 90% confidence interval
width for specificity of ± 1.5%.
Across all 3 groups, a total of 4133 participants are
required over a 5-year screening period. Assuming a
participation rate of 68%, a population size of 6077
CKD patients is required to achieve the target sample
size of 4133 for any meaningful analyses.
These sample sizes will provide 80% power to detect a
difference of between 3% and 4% in specificity between
groups of patients. The small number of expected cases
does not allow comparisons in sensitivity to be made
between groups.
Study design 2: Cost-effectiveness and cost-utility analyses
Using individually-collected clinical estimates such as
the prevalence of disease, the test sensitivity and specifi-
city of iFOBT, the screening participation rate, the prob-
ability of cancer and adenoma diagnoses, direct costs
estimates and utility weights from the diagnostic test
accuracy study and from published clinical estimates of
randomised controlled trials of screening, trial and mod-
elled -based cost-effectiveness and cost-utility analyses
will be conducted to estimates the efficiency of colorec-
tal cancer screening in CKD.
Probabilistic decision analytical models will be devel-
oped to estimate the incremental costs and health bene-
fits of screening compared with no screening in the
CKD population. Using time-dependent transition prob-
abilities, the models will provide the analytical frame-
work to simulate the natural history of colorectal
neoplasms, the screening and the diagnostic process and
the outcomes of colorectal neoplasms in individuals
with CKD.
Outcomes The outcomes of the study will include the
following
1. Healthcare costs of screening and no screening
2. Health outcomes (measured in survival and quality
adjusted survival) of screening and no screening
3. Incremental cost-effectiveness ratios as cost per life
year saved and cost per quality-adjusted life year gained
Study design 3: Qualitative in-depth interviews
This is a qualitative study to investigate the perspectives,
experiences, attitudes beliefs and preferences regarding
bowel cancer screening in individuals with CKD. Semi-
structured face-to-face interviews will be conducted
initially with 60 patients (30 participants, 30 non-partici-
pants will be sampled from all participating centres).
Participants will be purposively selected from the parti-
cipants and the non-participants of the diagnostic test
study (Study 1) to ensure a range of age, ethnicity, co-
morbidities and a balance of gender. Data collection will
cease when theoretical saturation is reached in the con-
current analysis, which is when little or no new concepts
emerge in subsequent interviews. The participants will
be asked for their perspectives on: a) knowledge about
bowel cancer risk and screening, b) reasons for partici-
pating/not participating in the diagnostic screening trial,
c) experiences of participating in the screening diagnos-
tic study, d) perceived benefits and harms in participat-
ing in screening. All interviews will be audio recorded
and transcribed verbatim. The computer software
‘HyperRESEARCH 3.0’ will be used to assist with sto-
rage, coding and searching of qualitative data. Coding
and analysis will accord to thematic analysis. The analy-
sis will be performed for all participants collectively;
then a sub-analysis will be conducted for screening par-
ticipants and non-participants to identify and compare
differences between both groups.
Outcomes The outcomes of the study will include the
following:
1. Identification of barriers and facilitators to partici-
pation in bowel cancer screening
2. Understanding of patients decision-making under-
pinning participation in cancer screening
3. Information to inform policy- and decision-makers
about a patient focussed screening program that takes
into consideration their needs, priorities and
preferences.
Ethical considerations The DETECT study protocol
has been approved by the Sydney West Area Health Ser-
vice Ethics Review Committee (HREC10/WMEAD/13
and SSA/10/WMEAD/54). The University of Sydney,
Human Research Ethics committee has also been noti-
fied of the approval. The screening test itself is mini-
mally invasive and will not impose any significant harms
to the patients. The diagnostic colonoscopies will be
performed by experienced gastroenterologists from all
Wong et al. BMC Public Health 2011, 11:516
http://www.biomedcentral.com/1471-2458/11/516
Page 5 of 7
participating centres, to prevent any significant compli-
cations such as catastrophic bleeding and bowel perfora-
tions. The investigator team will monitor all potential
electrolytes derrangement resulting from the bowel pre-
paration by collecting and monitoring pre and post-
operative serum biochemistry. Information sheets,
clearly and succinctly outlining the screening procedure
and the associated harms will be given to all eligible
patients to read. Patients are in no way obliged to parti-
cipate and if they do, they can withdraw at any time
from the study. They will be informed that their deci-
sion to withdraw will not result in any consequences
relating to their care provided. Summary of the monthly
progress report, outlining any potential complications/
harms will be given to all participants and their treating
physicians.
Discussion
The DETECT study is a detailed analysis of the diagnos-
tic test performance characteristics of iFOBT screening,
the costs and health benefits of screening in the CKD
population and of patient perspectives and preferences
regarding colorectal cancer screening. Specifically, this
proposed program of research will provide:
1. Estimates of the prevalence for pre-malignant and
malignant colorectal neoplasms in the CKD population
2. Estimates of test performance characteristics such
as test sensitivity and specificity of iFOBT screening in
individuals with CKD
3. Estimates of screening participation rate in people
with CKD
4. The incremental costs and health outcomes of
iFOBT screening in CKD
5. Patients’ perspectives, attitudes, beliefs experiences
and preferences regarding screening colorectal cancer
Findings of our research will address the critical issues
in chronic disease prevention in Australia and world-
wide. This project is uniquely placed to investigate the
evidence gaps surrounding the diagnostic test accuracy,
the costs and benefits and patients’ perspectives and
preferences for colorectal cancer screening, with the
ultimate objective being to improve the survival and
quality of life outcomes in patients with CKD.
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